RWC 2024 Plenary: Federal Response to Ending the HIV Epidemic

Panel of national leaders in the federal efforts to end the HIV epidemic. Speaker bios

Disponible en español / Available in Spanish

HRSA HIV/AIDS Bureau (HAB) Associate Administrator Dr. Laura Cheever

• The 34th anniversary of the Ryan White CARE Act (August 18, 2024), which created the RWHAP. 
• The latest HAB EHE data and how HRSA is challenging our RWHAP community to embrace the next step of work we need to do - reaching those not fully engaged in care.
• Unveiling of HRSA’s new Ryan White Program 2030 vision, which calls on the RWHAP community to both continue caring for people in the program while prioritizing efforts toward reaching people with HIV who are out of care by leveraging partnerships, focusing interventions, and engaging community to end the HIV epidemic.

HRSA Administrator Carole Johnson

• Acknowledgement of the incredible work of the RWHAP community and highlighted how the program has been instrumental to HRSA’s commitment to advancing equitable access to health care and to improving health outcomes for people with HIV. 
• The need for shared perspectives in the policy-making process. 
• Gratitude for the collaborations that are supporting communities with HIV, which are important as we work together to achieve the Ryan White Program 2030 vision. 

HHS Deputy Secretary Andrea Palm 

• Commendation of the work and successes of HRSA and other HHS agencies across the HIV treatment and prevention-treatment continuum.
• Announcement of over $1.4 billion in Ryan White HIV/AIDS Program funding for the HRSA AIDS Drug Assistance Program and related awards. This HRSA funding ensures that more than 290,000 individuals with HIV who have low incomes receive lifesaving medication, quality HIV health care, and essential support services.

Dr. Jeanne Marrazzo, Director, National Institute of Allergy and Infectious Diseases, National Institutes of Health

• Summary of the HIV landscape and the science and biomedical advancements in HIV. 
• Sharing of data and a rapid-fire review of research on treatment, prevention, and vaccine studies, focusing on two major components—closing implementation gaps and developing new and improved interventions.